Pharma-Bio Serv (PBSV) Gross Profit (2010 - 2026)

Pharma-Bio Serv (PBSV) has reported Gross Profit for 16 consecutive years, with $902041.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit rose 10.18% year-over-year to $902041.0; the trailing twelve-month figure through Apr 2026 stood at $2.9 million (changed 0.04% YoY), and the FY2025 full-year result was $2.9 million, up 15.66% from the prior year.
• Gross Profit climbed to $902041.0 in Q2 2026 per PBSV's latest filing, from $722374.0 in the prior quarter.
• Across five years, Gross Profit topped out at $1.6 million in Q3 2023 and bottomed at $535609.0 in Q1 2024.
• Historically, Gross Profit has averaged $944352.4 across 5 years, with a median of $860383.5 in 2025.
• The sharpest annual moves came in 2024 and 2025: Gross Profit slumped 59.01% in 2024, then soared 43.41% in 2025.
• Over 5 years, Gross Profit stood at $1.1 million in 2022, then dropped by 16.13% to $929805.0 in 2023, then slipped by 21.86% to $726570.0 in 2024, then climbed by 3.08% to $748935.0 in 2025, then rose by 20.44% to $902041.0 in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $902041.0, $722374.0, and $748935.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.